Bidding War: Private equity giants HIG and CapVest have entered a high-stakes bidding war for AAH Pharmaceuticals, the UK’s largest pharmacy wholesaler.
Company Profile: AAH services 14,000 pharmacies across the UK, generating £3 billion in annual revenue and delivering over 10 million items weekly.
Valuation Expectations: Aurelius aims to sell AAH for around £900 million, nearly double the £477 million it paid for the entire McKesson UK business in 2021.
Competitive Landscape: The UK pharmacy wholesaler market is highly competitive, with players like Phoenix and Alliance Healthcare vying for market share.
Growth Under Aurelius: Despite controversies, AAH has seen a 60% increase in active customer accounts since 2022, demonstrating resilience.
Strategic Implications: The auction outcome could reshape the industry, impacting employees, customers, and competitors through new investment strategies and operational efficiencies.
Regulatory Concerns: Analysts highlight the need for careful consideration of operational and reputational risks in such deals, given regulatory challenges.
Industry Trends: The auction reflects growing interest in strategic healthcare investments by private equity firms, signaling potential shifts in the sector.
Stakeholder Engagement: As the process unfolds, engaging with industry experts and stakeholders is crucial to understand the evolving strategies and implications.
Future Outlook: The auction’s outcome will be closely watched, offering insights into private equity firms’ strategic priorities in the healthcare sector.
Galderma Group AG agreed to acquire ZO Skin Health Inc. from Blackstone Tactical Opportunities and the Obagi family for an enterprise value of $1.5 billion. The all-cash transaction buys a...
BlackRock entered an agreement on October 13, 2026, to acquire the majority equity stake in a primary care joint venture from Welsh, Carson, Anderson & Stowe for $2.8 billion. The transaction...
STERIS Corporation, a wholly owned operating subsidiary of STERIS plc, agreed to buy Xodus Medical, Inc. for $2.1 billion in cash on October 12, 2026, according to a corporate press release...
Viatris Inc. agreed to purchase Pacira BioSciences Inc. for $36.50 per share in cash on October 8, 2026, establishing an equity valuation of approximately $1.65 billion. The transaction establishes...
